Effect  	Effect  	 NN	O
of  	of  	 IN	O
CYP1A2  	CYP1A2  	 CD	O
polymorphism  	polymorphism  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
pharmacokinetics  	pharmacokinetics  	 NN	B-NP
of  	of  	 IN	I-NP
agomelatine  	agomelatine  	 NN	I-NP
in  	in  	 IN	O
Chinese  	Chinese  	 JJ	O
healthy  	healthy  	 JJ	O
male  	male  	 JJ	O
volunteers  	volunteers  	 JJ	O
Agomelatine  	Agomelatine  	 NNP	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
melatonin  	melatonin  	 NN	B-NP
( 	( 	 -LRB-	O
MT 	MT 	 NNP	B-NP
)  	)  	 -RRB-	O
analogue  	analogue  	 NN	O
with  	with  	 IN	O
agonistic  	agonistic  	 JJ	B-NP
properties  	properties  	 NNS	I-NP
and  	and  	 CC	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
proven  	proven  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
effective  	effective  	 JJ	O
for  	for  	 IN	O
various  	various  	 JJ	O
types  	types  	 NNS	O
of  	of  	 IN	O
depressive  	depressive  	 JJ	B-NP
symptoms 	symptoms 	 NNS	I-NP
.  	.  	 .	O
Following  	Following  	 VBG	O
oral  	oral  	 JJ	B-NP
administration 	administration 	 NN	I-NP
,  	,  	 ,	O
agomelatine  	agomelatine  	 NN	B-NP
is  	is  	 VBZ	O
primarily  	primarily  	 RB	O
metabolized  	metabolized  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
hepatic  	hepatic  	 FW	O
cytochrome  	cytochrome  	 FW	O
P450  	P450  	 FW	O
isoenzyme  	isoenzyme  	 FW	O
CYP1A2 	CYP1A2 	 FW	O
.  	.  	 .	O
The  	The  	 DT	O
purpose  	purpose  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
study  	study  	 NN	O
was  	was  	 VBD	O
to  	to  	 TO	O
assess  	assess  	 VB	O
the  	the  	 DT	O
influence  	influence  	 NN	O
of  	of  	 IN	O
CYP1A2  	CYP1A2  	 CD	O
single  	single  	 JJ	B-NP
nucleotide  	nucleotide  	 JJ	I-NP
polymorphisms  	polymorphisms  	 NNS	I-NP
( 	( 	 -LRB-	O
SNPs 	SNPs 	 NNP	B-NP
,  	,  	 ,	O
rs762551 	rs762551 	 NNP	O
,  	,  	 ,	O
rs2069514 	rs2069514 	 NNP	O
,  	,  	 ,	O
rs2472304 	rs2472304 	 NNP	O
,  	,  	 ,	O
rs2470890 	rs2470890 	 CD	O
)  	)  	 -RRB-	O
on  	on  	 IN	O
agomelatine  	agomelatine  	 JJ	B-NP
pharmacokinetics  	pharmacokinetics  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
Chinese  	Chinese  	 JJ	O
population 	population 	 NN	O
.  	.  	 .	O
Seventy-two  	Seventy-two  	 JJ	O
healthy  	healthy  	 JJ	O
Chinese  	Chinese  	 JJ	O
male  	male  	 JJ	O
volunteers  	volunteers  	 NNS	O
enrolled  	enrolled  	 VBD	O
in  	in  	 IN	O
the  	the  	 DT	O
study  	study  	 NN	O
received  	received  	 VBD	O
an  	an  	 DT	O
oral  	oral  	 JJ	B-NP
dose  	dose  	 NN	I-NP
of  	of  	 IN	O
25 mg  	25 mg  	 CD	O
of  	of  	 IN	O
agomelatine  	agomelatine  	 NN	B-NP
after  	after  	 IN	O
providing  	providing  	 VBG	O
written  	written  	 VBN	O
informed  	informed  	 VBN	B-NP
consent 	consent 	 NN	I-NP
.  	.  	 .	O
CYP1A2  	CYP1A2  	 NNP	O
SNPs  	SNPs  	 NNP	O
were  	were  	 VBD	O
genotyped  	genotyped  	 VBN	O
by  	by  	 IN	O
polymerase  	polymerase  	 JJ	B-NP
chain  	chain  	 NN	I-NP
reaction-restriction  	reaction-restriction  	 JJ	I-NP
fragment  	fragment  	 NN	I-NP
length  	length  	 NN	I-NP
polymorphism  	polymorphism  	 NNS	I-NP
( 	( 	 -LRB-	O
PCR-RFLP 	PCR-RFLP 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Agomelatine  	Agomelatine  	 JJ	B-NP
plasma  	plasma  	 NN	I-NP
concentrations  	concentrations  	 NNS	I-NP
were  	were  	 VBD	O
determined  	determined  	 VBN	O
by  	by  	 IN	O
high  	high  	 JJ	O
performance  	performance  	 NN	O
liquid  	liquid  	 JJ	B-NP
chromatography-tandem  	chromatography-tandem  	 JJ	I-NP
mass  	mass  	 NN	I-NP
spectrometry 	spectrometry 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
pharmacokinetics  	pharmacokinetics  	 JJ	B-NP
analyses  	analyses  	 NNS	I-NP
were  	were  	 VBD	O
evaluated  	evaluated  	 VBN	O
by  	by  	 IN	O
nonparametric  	nonparametric  	 JJ	B-NP
methods 	methods 	 NNS	I-NP
.  	.  	 .	O
After  	After  	 IN	O
a  	a  	 DT	O
single  	single  	 JJ	O
oral  	oral  	 JJ	B-NP
dose  	dose  	 NN	I-NP
of  	of  	 IN	O
25 mg  	25 mg  	 CD	O
agomelatine 	agomelatine 	 NN	O
,  	,  	 ,	O
no  	no  	 DT	O
significant  	significant  	 JJ	O
differences  	differences  	 NNS	O
existed  	existed  	 VBD	O
in  	in  	 IN	O
agomelatine  	agomelatine  	 JJ	B-NP
pharmacokinetics  	pharmacokinetics  	 NN	I-NP
between  	between  	 IN	O
the  	the  	 DT	O
rs2069514  	rs2069514  	 FW	O
GG  	GG  	 FW	B-NP
homozygotes  	homozygotes  	 FW	I-NP
( 	( 	 -LRB-	O
n = 35 	n = 35 	 NNP	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
the  	the  	 DT	O
rs2069514  	rs2069514  	 NNP	O
AG  	AG  	 NNP	B-NP
allele  	allele  	 NNS	I-NP
( 	( 	 -LRB-	O
n = 35 	n = 35 	 NNP	O
)  	)  	 -RRB-	O
in  	in  	 IN	O
all  	all  	 DT	O
subjects 	subjects 	 NNS	B-NP
.  	.  	 .	O
The  	The  	 DT	O
mean  	mean  	 JJ	O
agomelatine  	agomelatine  	 JJ	B-NP
AUC0-7  	AUC0-7  	 NN	I-NP
,  	,  	 ,	O
AUC0-∞  	AUC0-∞  	 NNP	B-NP
and  	and  	 CC	O
Cmax  	Cmax  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
rs762551  	rs762551  	 FW	O
CC  	CC  	 FW	O
homozygotes  	homozygotes  	 FW	B-NP
( 	( 	 -LRB-	O
n = 9 	n = 9 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
rs2470890  	rs2470890  	 FW	O
CC  	CC  	 FW	O
homozygotes  	homozygotes  	 FW	B-NP
( 	( 	 -LRB-	O
n = 54 	n = 54 	 NNP	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
rs2472304  	rs2472304  	 NNP	O
GG  	GG  	 NNP	B-NP
homozygotes  	homozygotes  	 NNS	I-NP
( 	( 	 -LRB-	O
n = 51 	n = 51 	 NNP	O
)  	)  	 -RRB-	O
were  	were  	 VBD	O
much  	much  	 RB	O
higher  	higher  	 JJR	O
than  	than  	 IN	O
the  	the  	 DT	O
rs762551  	rs762551  	 JJ	B-NP
AA  	AA  	 NN	I-NP
allele  	allele  	 NNS	I-NP
( 	( 	 -LRB-	O
n = 31 	n = 31 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
rs2470890  	rs2470890  	 FW	O
CT  	CT  	 FW	B-NP
allele  	allele  	 FW	I-NP
( 	( 	 -LRB-	O
n = 17 	n = 17 	 NNP	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
rs2472304  	rs2472304  	 NNP	O
AG  	AG  	 NNP	B-NP
allele  	allele  	 NNS	I-NP
( 	( 	 -LRB-	O
n = 20 	n = 20 	 NNP	O
)  	)  	 -RRB-	O
respectively  	respectively  	 RB	O
( 	( 	 -LRB-	O
P   	P   	 NNP	O
< 	< 	 SYM	O
 0.05 	 0.05 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
rs762551  	rs762551  	 NNP	O
A 	A 	 NNP	O
,  	,  	 ,	O
rs2470890  	rs2470890  	 CD	O
T  	T  	 NN	O
and  	and  	 CC	O
rs2472304  	rs2472304  	 CD	O
A  	A  	 DT	O
genotype  	genotype  	 NN	B-NP
presented  	presented  	 VBD	O
a  	a  	 DT	O
significantly  	significantly  	 RB	O
lower  	lower  	 JJR	O
level  	level  	 NN	O
of  	of  	 IN	O
agomelatine  	agomelatine  	 JJ	B-NP
exposure  	exposure  	 NN	I-NP
( 	( 	 -LRB-	O
AUC 	AUC 	 NNP	B-NP
,  	,  	 ,	O
Cmax  	Cmax  	 NNP	B-NP
)  	)  	 -RRB-	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
rs762551  	rs762551  	 NNP	O
C 	C 	 NNP	O
,  	,  	 ,	O
rs2470890  	rs2470890  	 NNP	O
C  	C  	 NNP	O
and  	and  	 CC	O
rs2472304  	rs2472304  	 NNP	O
G  	G  	 NNP	B-NP
genotype  	genotype  	 NN	I-NP
in  	in  	 IN	O
Chinese  	Chinese  	 JJ	O
healthy  	healthy  	 JJ	O
subjects 	subjects 	 NNS	B-NP
.  	.  	 .	O
It  	It  	 PRP	O
suggested  	suggested  	 VBD	O
that  	that  	 IN	O
the  	the  	 DT	O
rs762551 	rs762551 	 NNP	O
,  	,  	 ,	O
rs2470890  	rs2470890  	 NNP	O
and  	and  	 CC	O
rs2472304  	rs2472304  	 CD	O
genetic  	genetic  	 JJ	B-NP
polymorphism  	polymorphism  	 NN	I-NP
might  	might  	 MD	O
be  	be  	 VB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
marked  	marked  	 JJ	O
interindividual  	interindividual  	 JJ	B-NP
variability  	variability  	 NN	I-NP
of  	of  	 IN	I-NP
agomelatine 	agomelatine 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
pharmacokinetic  	pharmacokinetic  	 JJ	B-NP
profile  	profile  	 NN	I-NP
of  	of  	 IN	I-NP
agomelatine  	agomelatine  	 NNS	I-NP
may  	may  	 MD	O
be  	be  	 VB	O
different  	different  	 JJ	O
in  	in  	 IN	O
different  	different  	 JJ	O
races 	races 	 NNS	O
.  	.  	 .	O
